Silencing of Human Phosphatidylethanolamine-Binding Protein 4 Enhances Rituximab-Induced Death and Chemosensitization in B-Cell Lymphoma

Rituximab is the first line drug to treat non Hodgkin’s lymphoma (B-NHL) alone or in combination with chemotherapy. However, 30–40% of B-NHL patients are unresponsive to rituximab or resistant after therapy. Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a novel member of PEBP family a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kai, Jiang, Yu, Zheng, Weiyan, Liu, Zhiyong, Li, Hui, Lou, Jianzhou, Gu, Meidi, Wang, Xiaojian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581549/
https://www.ncbi.nlm.nih.gov/pubmed/23451095
http://dx.doi.org/10.1371/journal.pone.0056829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581549/
https://www.ncbi.nlm.nih.gov/pubmed/23451095
http://dx.doi.org/10.1371/journal.pone.0056829

Ejemplares similares